What Does Farxiga Cost in 2026?

Farxiga (dapagliflozin) is an oral tablet taken once daily. AstraZeneca develops and markets the drug in the United States. As of 2026, it carries three FDA-approved indications: lowering blood sugar in adults and children aged 10 and older with type 2 diabetes mellitus; reducing the risk of sustained decline in kidney function, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease (CKD); and reducing the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF). Patients on Farxiga solely for heart failure or chronic kidney disease who do not have type 2 diabetes still qualify for the same Medicare pricing and cost-reduction programs.

Farxiga was selected as one of the first 10 drugs subject to Medicare price negotiation under the Inflation Reduction Act (Public Law 117-169, signed August 16, 2022). The negotiated Maximum Fair Price of $178.50 per 30-day supply took effect January 1, 2026. As a Part D drug (a self-administered oral tablet dispensed through retail pharmacies), Farxiga carries no HCPCS J-code and is not billed under Medicare Part D. Pricing flows entirely through retail pharmacy and Part D prescription drug plans. In a major development for patient cost, the FDA approved the first generic dapagliflozin tablets on April 7, 2026. As of mid-2026, generic prices range from $330 to $617 per month and are expected to decline as manufacturing competition expands. Jardiance, another SGLT2 inhibitor, also received an IRA-negotiated price for 2026.

Without insurance at a retail pharmacy, brand-name Farxiga runs $590 to $778 per month depending on the pharmacy and dosage strength (5 mg or 10 mg). With a free GoodRx discount coupon, the brand price drops to roughly $288 per month at participating pharmacies. The AstraZeneca SavingsRx card brings monthly cost to $0 for most commercially insured patients (savings up to $175 per 30-day supply). That card is not valid with Medicare, Medicaid, TRICARE, or any federal or state government health program under federal anti-kickback statute (42 U.S.C. Section 1320a-7b). The AZ&Me patient assistance program closed new Farxiga enrollments on May 1, 2026, due to the generic approval. Patients seeking no-cost medication should contact AstraZeneca patient support at 1-855-332-7944 to confirm current options. Low-income patients may also qualify for Medicaid coverage — see state income limits to check eligibility. Medicare patients who need cost-sharing help can apply for Extra Help.

What Farxiga Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same farxiga can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Farxiga is primarily a self-administered oral drug dispensed through retail pharmacies, so inpatient hospital billing is far less common than with injectable drugs. When a patient admitted to the hospital is already taking Farxiga at home, the hospital typically continues the prescription during the stay and bundles the drug charge into the DRG (Diagnosis-Related Group) payment under Medicare Part A. In those cases, the drug cost is absorbed into the facility payment and does not appear as a separate line on the patient bill.

When Farxiga does appear as a separate line item on a hospital bill, it is typically because the patient is being started on the drug during the admission, or the billing system has miscoded the stay as outpatient observation rather than inpatient. Hospital chargemasters list Farxiga at 1.5x to 3x the retail acquisition cost. A 30-day supply costing the hospital $400 to $550 at negotiated acquisition pricing may be billed to patients at $900 to $1,800. Patients who see Farxiga as a separate line item should request an itemized bill and compare each drug charge against the hospital's own price-transparency files, which CMS has required hospitals to post publicly since 2021.

One clinical note specific to SGLT2 inhibitors like Farxiga: CMS and clinical society guidelines recommend stopping SGLT2 inhibitors before surgery, prolonged fasting, or procedures with contrast dye due to the risk of euglycemic diabetic ketoacidosis (euDKA). If a patient is admitted for surgery, the hospital may legitimately hold Farxiga during the stay. Patients should verify they are not being billed for Farxiga doses during a hospitalization when the medication reconciliation documentation shows the drug was discontinued. Billing for Farxiga on days it was clinically held is a discrepancy worth disputing on the itemized bill.

Patient Assistance Programs

AstraZeneca's patient assistance landscape for Farxiga changed significantly in 2026. The AZ&Me Patient Assistance Program, which previously provided free Farxiga to income-eligible uninsured patients, stopped accepting new Farxiga enrollments effective May 1, 2026, citing the April 2026 FDA approval of generic dapagliflozin. Existing AZ&Me Farxiga patients may retain their enrollment through their current approval period. For new patients, AstraZeneca directs inquiries to its patient support line and the generic as the primary cost-reduction path. The manufacturer SavingsRx card for commercially insured patients remains active:

Medicare Part D

Farxiga is covered under Medicare Part D. Starting January 1, 2026, Medicare Part D enrollees benefit from the IRA-negotiated Maximum Fair Price of $178.50 per 30-day supply. All Part D plans, including Medicare Advantage prescription drug (MA-PD) plans, are required to honor this price by federal law. The actual out-of-pocket cost per fill varies by plan design and coverage phase. Enrollees who also receive the Low Income Subsidy (Extra Help) pay approximately $11 per prescription. All Part D enrollees are protected by the 2026 annual out-of-pocket cap of $2,100. After crossing that threshold, cost sharing drops to $0 for the rest of the year.

Before the IRA-negotiated price took effect, Medicare beneficiaries on Farxiga could face annual drug costs well above $5,000 before reaching the Part D catastrophic coverage phase. The negotiated $178.50 Maximum Fair Price represents a 68 percent reduction from the pre-negotiation list price of approximately $556. If your Medicare Part D plan charges more than $178.50 for a 30-day Farxiga fill in 2026, contact your plan's member services and request they apply the Maximum Fair Price. Plans are legally required to honor it. A discrepancy may reflect a formulary-tier coding error or a delay in applying the CMS-mandated price, both of which are correctable.

Common Farxiga Billing Errors

Farxiga is an oral tablet with no J-code, so the most common billing issues involve formulary tier errors, IRA price application failures, and generic substitution confusion. If your pharmacy or insurer charges more than expected for Farxiga, check for these:

• Part D plan charged more than $178.50 per 30-day fill in 2026: the Maximum Fair Price is federally mandated for all Part D plans; request the plan apply the MFP and file a coverage determination dispute if declined
• Wrong formulary tier applied: Farxiga placed on Tier 4 or Tier 5 (specialty tier) instead of Tier 2 or Tier 3, which inflates cost-sharing significantly above the $178.50 MFP
• Generic dapagliflozin dispensed without patient consent: some pharmacies may substitute the generic for brand Farxiga automatically; patients prescribed Farxiga for a specific reason (such as a labeled indication not covered by a particular generic's labeling) should confirm with their prescriber whether generic substitution is appropriate
• Pharmacy substituted Jardiance (empagliflozin) for Farxiga without prescriber authorization: different SGLT2 inhibitors are not therapeutically interchangeable across all approved indications
• Manufacturer copay card denied due to plan accumulator adjustment program: if your commercial plan uses an accumulator adjuster, the SavingsRx card payments may not count toward your deductible; contact your plan's pharmacy benefit manager for clarification
• Inpatient billing for Farxiga on days the drug was clinically held: SGLT2 inhibitors are routinely discontinued before surgery and procedures; if your bill shows Farxiga on dates when your medication reconciliation note says it was held, dispute those line items

Frequently Asked Questions